Clinical Trial Update: SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SPD503 in children and adolescents with generalized anxiety disorder, separation anxiety disorder, or social phobia; study com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder
• Separation Anxiety Disorder
• Social Phobia

Drugs mentioned

• SPD503

Snippet

Sponsor: Shire | Conditions: Generalized Anxiety Disorder (GAD), Anxiety, Separation | Phase 2 | Status: COMPLETED | Results posted: 2014-05-23